 Carcinoma, Renal Cell
"Carcinoma, Renal Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Descriptor ID |
D002292
|
| MeSH Number(s) |
C04.557.470.200.025.390 C04.588.945.947.535.160 C12.758.820.750.160 C12.777.419.473.160 C13.351.937.820.535.160 C13.351.968.419.473.160
|
| Concept/Terms |
Carcinoma, Renal Cell- Carcinoma, Renal Cell
- Carcinomas, Renal Cell
- Renal Cell Carcinomas
- Adenocarcinoma, Renal Cell
- Adenocarcinomas, Renal Cell
- Renal Cell Adenocarcinoma
- Renal Cell Adenocarcinomas
- Adenocarcinoma Of Kidney
- Adenocarcinoma Of Kidneys
- Kidney, Adenocarcinoma Of
- Kidneys, Adenocarcinoma Of
- Renal Cell Cancer
- Cancer, Renal Cell
- Cancers, Renal Cell
- Renal Cell Cancers
- Adenocarcinoma, Renal
- Adenocarcinomas, Renal
- Renal Adenocarcinoma
- Renal Adenocarcinomas
- Nephroid Carcinoma
- Carcinoma, Nephroid
- Carcinomas, Nephroid
- Nephroid Carcinomas
- Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma- Clear Cell Renal Cell Carcinoma
- Grawitz Tumor
- Tumor, Grawitz
- Clear Cell Renal Carcinoma
- Carcinoma, Hypernephroid
- Carcinomas, Hypernephroid
- Hypernephroid Carcinoma
- Hypernephroid Carcinomas
- Hypernephroma
- Hypernephromas
Collecting Duct Carcinoma (Kidney)- Collecting Duct Carcinoma (Kidney)
- Carcinoma, Collecting Duct (Kidney)
- Carcinomas, Collecting Duct (Kidney)
- Collecting Duct Carcinomas (Kidney)
- Collecting Duct Carcinoma of the Kidney
- Renal Collecting Duct Carcinoma
- Collecting Duct Carcinoma
- Carcinoma, Collecting Duct
- Carcinomas, Collecting Duct
- Collecting Duct Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Renal Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Renal Cell".
This graph shows the total number of publications written about "Carcinoma, Renal Cell" by people in this website by year, and whether "Carcinoma, Renal Cell" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 | | 1998 | 2 | 0 | 2 | | 1999 | 2 | 0 | 2 | | 2000 | 2 | 1 | 3 | | 2001 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 0 | 2 | | 2006 | 1 | 1 | 2 | | 2007 | 3 | 0 | 3 | | 2008 | 4 | 0 | 4 | | 2009 | 2 | 1 | 3 | | 2010 | 4 | 0 | 4 | | 2011 | 3 | 1 | 4 | | 2012 | 6 | 1 | 7 | | 2013 | 8 | 2 | 10 | | 2014 | 11 | 0 | 11 | | 2015 | 9 | 0 | 9 | | 2016 | 4 | 0 | 4 | | 2017 | 3 | 0 | 3 | | 2018 | 6 | 0 | 6 | | 2019 | 9 | 0 | 9 | | 2020 | 13 | 0 | 13 | | 2021 | 12 | 1 | 13 | | 2022 | 17 | 0 | 17 | | 2023 | 8 | 0 | 8 | | 2024 | 15 | 1 | 16 | | 2025 | 14 | 0 | 14 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Renal Cell" by people in Profiles.
-
Musso G, Garofano G, Dabbas M, Meagher MF, Yuen KL, Birouty N, Baker B, Saitta C, Guer M, Montorsi F, Briganti A, Capitanio U, Larcher A, Salonia A, Derweesh IH. The Influence of Lymphovascular Invasion on T Stage Upstaging and Overall Survival in Renal Cell Carcinoma: A Population-Based Study. Clin Genitourin Cancer. 2025 Oct; 23(5):102412.
-
Massari F, Mollica V, Kopp RM, Grande E, Fiala O, Kanesvaran R, Li H, Schieber TJ, Juan Fita MJ, Poprach A, Lolli C, Bourlon MT, de Liaño AG, Grillone F, Sunela K, Rizzo A, Ghosn M, Cerbone L, Taha T, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, Lenci E, Martin IO, Abu-Sini H, Rescigno P, Bhuva D, Fay AP, Conteduca V, Yildirim A, Rosellini M, Akova U, Tassinari E, Bölek H, Soares A, Marques Monteiro FS, Buti S, Bilen MA, Santoni M. Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study. Eur Urol Focus. 2025 Sep; 11(5):736-746.
-
Musso G, Birouty N, Salonia A, Garofano G, Dabbas M, Meagher MF, Yuen KL, Baker B, Saitta C, Patil D, Tanaka H, Kobayashi M, Fukuda S, Montorsi F, Briganti A, Capitanio U, Larcher A, Rosiello G, Fujii Y, Master VA, Derweesh IH. Association of Elevated Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte, and De Ritis Ratios With Major Complications After Surgery for Renal Cell Carcinoma: A Pathway to Optimize Charlson Comorbidity Index and Preoperative Predictive Modeling. Urology. 2025 Nov; 205:99-107.
-
Saitta C, Garofano G, Musso G, Tanaka H, Patil D, Nguyen V, Yuen KL, Baker B, Dabbas M, Meagher MF, Puri D, Birouty N, Baker O, Kobayashi M, Fukuda S, Paciotti M, Lughezzani G, Larcher A, Capitanio U, Melloni R, Catanzaro M, Nazzani S, Nicolai N, Fujii Y, Master V, Buffi N, Derweesh IH. UNIK (Urologic Non-Neoplastic Investigation of Kidneys): a machine learning approach to decode benign lesion. World J Urol. 2025 Jun 04; 43(1):355.
-
Garofano G, Saitta C, Musso G, Meagher MF, Capitanio U, Puri D, Dabbas M, Birouty N, Yuen KL, Larcher A, Baker B, Autorino R, Pandolfo SD, Montorsi F, Lughezzani G, Casale P, Buffi NM, Derweesh IH. Nomogram for predicting long-term survival in renal cell carcinoma patients undergoing thermal ablation. Urol Oncol. 2025 Sep; 43(9):524.e9-524.e16.
-
Gouda MA, Voss MH, Tawbi H, Gordon M, Tykodi SS, Lam ET, Vaishampayan U, Tannir NM, Chaves J, Nikolinakos P, Fan A, Lee R, McDermott D, Shapiro GI, Gandhi L, Bhatia S, Katragadda V, Meric-Bernstam F. A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open. 2025 May; 10(5):104536.
-
Porta C, Massari F, Taha T, Grande E, Bourlon MT, Kanesvaran R, Basso U, Molina-Cerrillo J, Alonso-Gordoa T, Myint ZW, Fornarini G, Buttner T, Park SH, Ürün Y, De Giorgi U, Pichler R, Rescigno P, Buchler T, Studentova H, Melichar B, Ansari J, Mollica V, Kucharz J, Rizzo M, Rizzo A, Kopp RM, Buti S, Monteiro FSM, Soares A, Bamias A, Santoni M. Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study. Cancer Immunol Immunother. 2025 May 09; 74(7):196.
-
Musso G, Meagher MF, Yuen KL, Baker B, Baker O, Ahdoot A, Puri D, Dabbas M, Birouty N, Saitta C, Guer M, Patil D, Tanaka H, Kobayashi M, Fukuda S, Montorsi F, Briganti A, Salonia A, Capitanio U, Larcher A, Fujii Y, Master V, Derweesh IH. Paraneoplastic and symptomatic score (PRIMAL) for prediction of overall and cancer-specific survival after surgery in patients with renal cell carcinoma. Urol Oncol. 2025 08; 43(8):470.e1-470.e9.
-
Wang X, Hasler J, Miron B, Wang M, Afghahi A, Royce TJ, Geynisman DM. Impact of Renal Function Eligibility Criteria on Clinical Trials and Real-World Survival Outcomes Among Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2025 Aug; 23(4):102362.
-
Powles T, Choueiri TK, Albiges L, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüs M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Rizzo M, Shinde R, Saretsky TL, He L, Perini RF, Vickery D, Rini B. Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Apr; 26(4):491-502.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|